|
rs121913377
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
In addition, Hashimoto's thyroiditis was related to less lymph node metastasis and extrathyroidal extension in PTCs with BRAF(V6</span>00E) mutation.
|
26041461 |
2016 |
|
rs121913377
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
We detected a BRAF V600E mutation by Sanger sequencing in the second primary and distant lymph node metastases, but not in the first primary or sentinel lymph node.
|
30222690 |
2019 |
|
rs121913377
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF(V600E) mutation was associated with male sex (P = 0.028), large tumor size, extrathyroidal extension, central and lateral lymph node metastasis, and advanced tumor stage (P<0.0001).
|
25337709 |
2014 |
|
rs121913377
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Moreover, BRAF(V600E) mutation was not correlated with any of the prognostic factors including age ≥45 years, male gender, tumor size ≥1cm, multifocality, extra-thyroidal extension, concurrent Hashimoto's thyroiditis, and lymph node metastasis neither in the univariate nor in the multivariate analysis.
|
21862261 |
2012 |
|
rs121913377
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E was associated with aggressive tumor factors, including lymph node metastasis (P=0.001) and advanced disease stage (P=0.009).
|
31602213 |
2019 |
|
rs121913377
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Tumor size correlated significantly with multifocality, extrathyroidal extension, and lymph node metastasis (P = 0.003, P < 0.001 and P < 0.001, respectively), but the BRAF V600E mutation status was not associated with any of those features.
|
22500044 |
2012 |
|
rs121913377
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.
|
26950846 |
2016 |
|
rs121913377
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
One case not meeting criteria for NIFTP maintained the diagnosis of encapsulated FVPTC without invasion but demonstrated significant mitotic activity (three mitoses/ten HPF) and lacked lymph node metastases and BRAF V600E mutation.
|
29368294 |
2018 |
|
rs121913377
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Increased EHD2 mRNA expression level was associated with extrathyroidal extension (p < 0.001), pT3-4 (p < 0.001), lymph node metastasis (p < 0.001), higher risk of recurrence (p < 0.001), and BRAF V600E (p < 0.001).
|
28358874 |
2017 |
|
rs121913377
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
The percentage of BRAF(V600E) alleles (P = 0.014), tumor volume (P = 0.012), and lymph node metastasis (P = 0.008) predicted the disease outcome.
|
22508706 |
2012 |
|
rs121913377
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF(V600E) mutation, BRAF V600E IHC, low ΔCt, and high BRAF RNA ISH were significantly associated with lymph node metastasis.
|
25468810 |
2015 |
|
rs121913377
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
On univariate analysis, the BRAF(V600E) mutation was associated with extrathyroidal extension (P = .009) and variants of PTC (P = .019), but a high-risk Metastasis, Patient Age, Completeness of resection, local Invasion and Tumor Size (MACIS) score (≥ 6) (P = .146) and lymph node metastasis (P = .628) were not significantly associated with the BRAF(V600E) mutation.
|
21803329 |
2012 |
|
rs121913377
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
We previously described a patient with BRAF V600E mutation in primary tumor and a new mutation (V600E+K601del) in the matched-lymph node metastases.
|
19169486 |
2008 |
|
rs121913377
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Furthermore, PTCs exhibiting BRAF V600E mutation (p = 0.01), ETE (p < 0.01), and lymph node metastasis (p = 0.02) were associated with higher ICAM-1 levels.
|
21879273 |
2012 |
|
rs121913377
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases.
|
16179870 |
2005 |
|
rs121913377
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Lymph node metastasis and BRAF V600E mutations were more frequent in papillary thyroid cancers with high LOC100507661 expression.
|
27151833 |
2016 |
|
rs121913377
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF c.1799T>A (p.Val600Glu) substitution was present in 59.0% Chinese PTCs, more frequently observed in patients with lymph node metastasis (P = 1.6 × 10(-4)).
|
26941397 |
2016 |
|
rs121913377
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
We found significant association between BRAF (V600E) mutation and age (P < 0.0001), extrathyroidal invasion (P = 0.017), lymph node metastasis (P = 0.038) and TNM stage III/IV (P = 0.001).
|
27387551 |
2016 |
|
rs121913377
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation: Differential impact on central lymph node metastasis by tumor size in papillary thyroid carcinoma.
|
26268700 |
2016 |
|
rs121913377
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
The status of BRAF(V600E) mutation was more frequent in multifocal PTC patients with lymph node metastasis and diagnosis at later age.
|
23253715 |
2012 |
|
rs121913377
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Significant correlation was observed between the expression of 2 lncRNAs (XLOC_051122 and XLOC_006074) and 1) lymph node metastasis (N stage) and 2) BRAF(V600E) mutation.
|
27459529 |
2016 |
|
rs121913377
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E) in PTC predicts an increased risk of lymph node metastasis, extra-thyroidal extension and reduced disease-free survival.
|
27138882 |
2016 |
|
rs121913377
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Expression of BRAF V600E, RET/PTC, and concomitant expression of BRAF V600E and RET/PTC were significantly associated with patient age and lymph node metastasis (P<0.05).
|
30254191 |
2018 |
|
rs121913377
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E) mutation-positive cancers (55.3%) were more frequently associated with lymph node metastasis (p=0.01) and advanced TNM stage (III-IV) (p=0.03).
|
24787545 |
2014 |
|
rs121913377
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
We analyzed the expression of S100A4, cyclin D1, p27 and MUC1, the presence of the BRAF V600E mutation and the clinicopathological features of the tumors, including patient age, tumor size (>or=5 vs <5 mm), extrathyroidal extension, multifocality, histological subtype, sclerosis and encapsulation, in a series of 198 papillary microcarcinomas in relation to lymph node metastasis to determine the predictive factors of lymph node metastasis.
|
18360353 |
2008 |